Accelovance named finalist for Best Contract Research Organization in ViE Awards Accelovance.

Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan health care policy research firm unaffiliated with Kaiser Permanente.. Accelovance named finalist for Best Contract Research Organization in ViE Awards Accelovance, a therapeutically focused agreement research organization , has been named a finalist for Best Contract Analysis Organization in the upcoming Vaccine Sector Excellence Awards hosted by the World Vaccine Congress. This is the eighth consecutive season Accelovance has been honored as a finalist for the award, earning for Best Contract Research Organization in 2009 2009, 2010, and 2011, and finding a STRONGLY SUGGESTED distinction in 2013.This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is an application of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.

Coagadex Approved for Rare Clotting Disorder: – WEDNESDAY, Oct. 21, 2015 – – Coagadex has been authorized by the U.S. Food and Drug Administration because the first coagulation element replacement therapy for those who have a rare bloodstream disorder known as hereditary Factor X insufficiency. The Aspect X protein helps blood coagulum. But among people with the inherited disorder, the blood does clot, which can lead to dangerous bleeding episodes.